### TABLE 1—REGISTRATION REVIEW INTERIM DECISIONS BEING ISSUED—Continued

<table>
<thead>
<tr>
<th>Registration review case name and number</th>
<th>Docket ID number</th>
<th>Chemical review manager and contact information</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fludioxonil, Case 7017</td>
<td>EPA–HQ–OPP–2014–0105.</td>
<td>Susanne Cerrelli, <a href="mailto:cerrelli.susanne@epa.gov">cerrelli.susanne@epa.gov</a>, (703) 308–8077</td>
</tr>
<tr>
<td>Sodium carbonate, Case 4066</td>
<td>EPA–HQ–OPP–2013–0137.</td>
<td>SanYvette Williams, <a href="mailto:williams.sanyvette@epa.gov">williams.sanyvette@epa.gov</a>, (703) 305–7702</td>
</tr>
<tr>
<td>TFM, Case 3082</td>
<td></td>
<td>R. David Jones, <a href="mailto:jones.rdavid@epa.gov">jones.rdavid@epa.gov</a>, (703) 305–6725</td>
</tr>
</tbody>
</table>

The proposed interim registration review decision for the chemicals in the table above were posted to the dockets for the public to submit comments or new information. EPA addressed the comments or new information received during the comment period for the proposed interim decisions. Comments from the 60-day comment period that were received may or may not have affected the Agency’s interim decisions. Pursuant to 40 CFR 155.58(c), the registration review case docket for chemicals listed in the table will remain open until all actions required in the interim decision have been completed.

This document also announces the closing of the registration review case for Bis (bromoacetoxy)-2-butene (BBAB) (Case 3030, Docket ID Number EPA–HQ–OPP–2014–0799), because the last U.S. registrations for these pesticides have been canceled. Background on the registration review program is provided at: [http://www.epa.gov/pesticide-reevaluation](http://www.epa.gov/pesticide-reevaluation).

**Authority:** 7 U.S.C. 136 et seq.


Yu-Ting Guilaran, Director, Pesticide Re-Evaluation Division, Office of Pesticide Programs.

**FEDERAL RESERVE SYSTEM**

**Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The applications will also be available for inspection at the offices of the Board of Governors not later than December 31, 2018.

**Applications.Comments@atl.frb.org:**

A. Federal Reserve Bank of Atlanta
   (Kathy Haney, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to Applications.Comments@atl.frb.org:
   
   1. B.P.C. Corporation, Cookeville, Tennessee; to merge with CFB Bancshares, Inc., and thereby indirectly acquire Citizens First Bank, both of Wartburg, Tennessee.


   Yao-Chin Chao,
   Assistant Secretary of the Board.
   [FR Doc. 2018–26328 Filed 12–3–18; 8:45 am]

**BILLING CODE P**

**GENERAL SERVICES ADMINISTRATION**

[Notice—MA–2018–10; Docket No. 2018–0002; Sequence No. 28]

**Relocation Allowances: Taxes on Travel, Transportation, and Relocation Expenses**

**AGENCY:** Office of Government-wide Policy (OGP), General Services Administration (GSA).
DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Supplemental Evidence and Data Request on Interventions for Substance Use Disorders in Adolescents: A Systematic Review

AGENCY: Agency for Healthcare Research and Quality (AHRQ), HHS.

ACTION: Request for supplemental evidence and data submissions.

SUMMARY: The Agency for Healthcare Research and Quality (AHRQ) is seeking scientific information submissions from the public. Scientific information is being solicited to inform our review of Interventions for Substance Use Disorders in Adolescents: A Systematic Review, which is currently being conducted by the AHRQ’s Evidence-based Practice Centers (EPC) Program. Access to published and unpublished pertinent scientific information will improve the quality of this review.

DATES: Submission Deadline on or before January 3, 2019.

ADDRESSES: Email submissions: epc@ahrq.hhs.gov.
Print submissions: Mailing Address: Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E53A, Rockville, MD 20857.
Shipping Address (FedEx, UPS, etc.): Center for Evidence and Practice Improvement, Agency for Healthcare Research and Quality, ATTN: EPC SEADs Coordinator, 5600 Fishers Lane, Mail Stop 06E77D, Rockville, MD 20857.

FOR FURTHER INFORMATION CONTACT: Jenae Benns, Telephone: 301–427–1496 or Email: epc@ahrq.hhs.gov.

SUPPLEMENTARY INFORMATION: The Agency for Healthcare Research and Quality has commissioned the Evidence-based Practice Centers (EPC) Program to complete a review of the evidence for Interventions for Substance Use Disorders in Adolescents: A Systematic Review. AHRQ is conducting this systematic review pursuant to Section 902(a) of the Public Health Service Act, 42 U.S.C. 299a(a).

The EPC Program is dedicated to identifying as many studies as possible that are relevant to the questions for each of its reviews. In order to do so, we are supplementing the usual manual and electronic database searches of the literature by requesting information from the public (e.g., details of studies conducted). We are looking for studies that report on Interventions for Substance Use Disorders in Adolescents: A Systematic Review, including those that describe adverse events. The entire research protocol, including the key questions, is also available online at: https://effectivehealthcare.ahrq.gov/topics/substance-use-disorders-adolescents/protocol.

This is to notify the public that the EPC Program would find the following information on Interventions for Substance Use Disorders in Adolescents: A Systematic Review helpful:

- A list of completed studies that your organization has sponsored for this indication. In the list, please indicate whether results are available on ClinicalTrials.gov along with the ClinicalTrials.gov trial number.

- For completed studies that do not have results on ClinicalTrials.gov, please provide a summary, including the following elements: study number, study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, primary and secondary outcomes, baseline characteristics, number of patients screened/eligible/enrolled/lost to follow-up/withdrawn/analyzed, effectiveness/efficacy, and safety results.

A list of ongoing studies that your organization has sponsored for this indication. In the list, please provide the ClinicalTrials.gov trial number or, if the trial is not registered, the protocol for the study including a study number, the study period, design, methodology, indication and diagnosis, proper use instructions, inclusion and exclusion criteria, and primary and secondary outcomes.

- Description of whether the above studies constitute ALL Phase II and above clinical trials sponsored by your organization for this indication and an index outlining the relevant information in each submitted file.

Your contribution will be very beneficial to the EPC Program. Materials submitted must be publicly available or able to be made public. Materials that are considered confidential; marketing materials; study types not included in the review; or information on indications not included in the review cannot be used by the EPC Program.

This is a voluntary request for information, and all costs for complying with this request must be borne by the submitter.

The draft of this review will be posted on AHRQ’s EPC Program website and available for public comment for a period of 4 weeks. If you would like to be notified when the draft is posted, please sign up for the email list at: https://effectivehealthcare.ahrq.gov/email-updates.

The systematic review will answer the following questions. This information is provided as background. AHRQ is not requesting that the public provide answers to these questions.

The Key Questions

KQ 1: What are the effects of behavioral, pharmacologic, and combined interventions compared with placebo or no active treatment for substance use disorders and problematic substance use in adolescents to achieve abstinence, reduce quantity and frequency of use, improve functional outcomes, and reduce substance-related harms?

- a. How do benefits and adverse outcomes of interventions vary by subpopulations?

1 Substances considered: Alcohol, cannabis, opioids, sedatives/hypnotics/annxiolytics, stimulants, inhalants and hallucinogens. Tobacco is excluded.

2 Subpopulations considered: Psychiatric comorbidities, age (early, middle and late